Certified by Founder Lodge
Ancilia Biosciences
United States - New York, New York
START UP
1 Disclosed Funding Rounds $4,200,000
0 Participating Investments
-
Founded date
2019
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Ancilia is harnessing the natural power of CRISPR to develop a new class of bacterial therapies and products for a range of applications.
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| August, 29 ,2024 | Unknown | $4,200,000 |
Metaplanet
Safar Partners
Spacecadet
Zubi Capital
PsyMed Ventures
IDRx
CAMP4 Therapeutics
Delfi Diagnostics
xilis
Manifold Bio
Rork | $15,000,000 | (Apr 10, 2026)
Plume (YC S24) | $3,900,000 | (Apr 10, 2026)
Haast | $12,000,000 | (Apr 10, 2026)
CareGlance Srl | $4,092,182 | (Apr 10, 2026)
Sigma Automate | $2,750,000 | (Apr 10, 2026)